FR2490494A1 - Agent pour ameliorer la circulation sanguine peripherique - Google Patents
Agent pour ameliorer la circulation sanguine peripherique Download PDFInfo
- Publication number
- FR2490494A1 FR2490494A1 FR8118140A FR8118140A FR2490494A1 FR 2490494 A1 FR2490494 A1 FR 2490494A1 FR 8118140 A FR8118140 A FR 8118140A FR 8118140 A FR8118140 A FR 8118140A FR 2490494 A1 FR2490494 A1 FR 2490494A1
- Authority
- FR
- France
- Prior art keywords
- agent
- blood
- gelatin
- blood circulation
- collagen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000017531 blood circulation Effects 0.000 title claims abstract description 11
- 210000005259 peripheral blood Anatomy 0.000 title abstract description 5
- 239000011886 peripheral blood Substances 0.000 title abstract description 5
- 102000008186 Collagen Human genes 0.000 claims abstract description 35
- 108010035532 Collagen Proteins 0.000 claims abstract description 35
- 229920001436 collagen Polymers 0.000 claims abstract description 35
- 108010010803 Gelatin Proteins 0.000 claims abstract description 30
- 229920000159 gelatin Polymers 0.000 claims abstract description 30
- 239000008273 gelatin Substances 0.000 claims abstract description 30
- 235000019322 gelatine Nutrition 0.000 claims abstract description 30
- 235000011852 gelatine desserts Nutrition 0.000 claims abstract description 30
- 239000008280 blood Substances 0.000 claims abstract description 22
- 210000004369 blood Anatomy 0.000 claims abstract description 21
- 150000001875 compounds Chemical class 0.000 claims abstract description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 18
- 239000000243 solution Substances 0.000 claims description 18
- 239000000203 mixture Substances 0.000 claims description 10
- 230000004087 circulation Effects 0.000 claims description 8
- 238000002347 injection Methods 0.000 claims description 6
- 239000007924 injection Substances 0.000 claims description 6
- 238000012423 maintenance Methods 0.000 claims description 4
- 210000000170 cell membrane Anatomy 0.000 claims description 3
- 230000003750 conditioning effect Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000001914 filtration Methods 0.000 abstract description 16
- 210000003743 erythrocyte Anatomy 0.000 description 34
- 206010018910 Haemolysis Diseases 0.000 description 18
- 230000008588 hemolysis Effects 0.000 description 18
- 239000000126 substance Substances 0.000 description 17
- 239000012528 membrane Substances 0.000 description 15
- 230000000694 effects Effects 0.000 description 13
- 238000000034 method Methods 0.000 description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 239000002504 physiological saline solution Substances 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 6
- 210000004180 plasmocyte Anatomy 0.000 description 6
- 230000036772 blood pressure Effects 0.000 description 5
- 238000007912 intraperitoneal administration Methods 0.000 description 5
- 210000002381 plasma Anatomy 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 241001494479 Pecora Species 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 210000000601 blood cell Anatomy 0.000 description 4
- 239000000470 constituent Substances 0.000 description 4
- 230000004089 microcirculation Effects 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000015271 coagulation Effects 0.000 description 3
- 238000005345 coagulation Methods 0.000 description 3
- 229960000633 dextran sulfate Drugs 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000001361 intraarterial administration Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 238000010253 intravenous injection Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 230000035322 succinylation Effects 0.000 description 3
- 238000010613 succinylation reaction Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 208000031220 Hemophilia Diseases 0.000 description 2
- 208000009292 Hemophilia A Diseases 0.000 description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000007059 acute toxicity Effects 0.000 description 2
- 231100000403 acute toxicity Toxicity 0.000 description 2
- 230000004520 agglutination Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 229960002086 dextran Drugs 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 108010074605 gamma-Globulins Proteins 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 238000005461 lubrication Methods 0.000 description 2
- 210000004088 microvessel Anatomy 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 206010065929 Cardiovascular insufficiency Diseases 0.000 description 1
- 206010008132 Cerebral thrombosis Diseases 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 241000270722 Crocodylidae Species 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108010064983 Ovomucin Proteins 0.000 description 1
- 102000016387 Pancreatic elastase Human genes 0.000 description 1
- 108010067372 Pancreatic elastase Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000012891 Ringer solution Substances 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000000823 artificial membrane Substances 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000002612 cardiopulmonary effect Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- LNNWVNGFPYWNQE-GMIGKAJZSA-N desomorphine Chemical compound C1C2=CC=C(O)C3=C2[C@]24CCN(C)[C@H]1[C@@H]2CCC[C@@H]4O3 LNNWVNGFPYWNQE-GMIGKAJZSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 208000009190 disseminated intravascular coagulation Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000022244 formylation Effects 0.000 description 1
- 238000006170 formylation reaction Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 230000003836 peripheral circulation Effects 0.000 description 1
- 230000001830 phrenic effect Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 229940014800 succinic anhydride Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- BFKJFAAPBSQJPD-UHFFFAOYSA-N tetrafluoroethene Chemical group FC(F)=C(F)F BFKJFAAPBSQJPD-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 201000005060 thrombophlebitis Diseases 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP55132336A JPS5767521A (en) | 1980-09-25 | 1980-09-25 | Agent for improving circulation blood vessel |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FR2490494A1 true FR2490494A1 (fr) | 1982-03-26 |
| FR2490494B1 FR2490494B1 (cg-RX-API-DMAC7.html) | 1984-12-21 |
Family
ID=15078940
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR8118140A Granted FR2490494A1 (fr) | 1980-09-25 | 1981-09-25 | Agent pour ameliorer la circulation sanguine peripherique |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US4446136A (cg-RX-API-DMAC7.html) |
| JP (1) | JPS5767521A (cg-RX-API-DMAC7.html) |
| CA (1) | CA1188222A (cg-RX-API-DMAC7.html) |
| CH (1) | CH649221A5 (cg-RX-API-DMAC7.html) |
| DE (1) | DE3138094A1 (cg-RX-API-DMAC7.html) |
| FR (1) | FR2490494A1 (cg-RX-API-DMAC7.html) |
| GB (1) | GB2086724B (cg-RX-API-DMAC7.html) |
| IT (1) | IT1195970B (cg-RX-API-DMAC7.html) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0330389A3 (en) * | 1988-02-18 | 1990-05-16 | Autogenesis Technologies, Inc. | Human collagen processing and autoimplant use |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL104670A (en) * | 1993-02-09 | 1998-04-05 | Travenol Lab Israel Ltd | Leukocyte removal method and filter unit for same |
| DE19735460A1 (de) | 1997-08-16 | 1999-02-18 | Rolf Prof Dr Med Zander | Spül- oder Lagerungsflüssigkeit für Blutzellen |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR4072M (cg-RX-API-DMAC7.html) * | 1963-06-04 | 1966-04-12 | ||
| FR1529055A (fr) * | 1966-06-18 | 1968-06-14 | Bayer Ag | Procédé pour fabriquer des solutions de gélatine sans agents pyrogènes utilisables comme préparations remplaçant le sang |
| FR2042381A1 (cg-RX-API-DMAC7.html) * | 1969-04-28 | 1971-02-12 | Knox Gelatine Inc | |
| FR2244809A1 (cg-RX-API-DMAC7.html) * | 1973-09-26 | 1975-04-18 | Hausmann Ag Labor | |
| DE2405002A1 (de) * | 1974-02-02 | 1975-08-14 | Trommsdorff Fa H | Loeslichen natives kollagen aus humangewebe und verfahren zu dessen herstellung |
| US3949073A (en) * | 1974-11-18 | 1976-04-06 | The Board Of Trustees Of Leland Stanford Junior University | Process for augmenting connective mammalian tissue with in situ polymerizable native collagen solution |
| DE2462222A1 (de) * | 1974-02-02 | 1976-05-06 | Trommsdorff Fa H | Loesliches, natives human-kollagen, dessen nicht-helikale peptide teilweise oder vollstaendig abgetrennt sind |
| FR2301568A1 (fr) * | 1975-02-18 | 1976-09-17 | Warner Lambert Co | Composition renfermant du collagene soluble et procede de sa preparation |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2591133A (en) * | 1950-05-29 | 1952-04-01 | California Inst Res Found | Method of producing gelatin derivative |
| GB886553A (en) * | 1958-01-22 | 1962-01-10 | Hoechst Ag | Substitutes for blood plasma and process for their manufacture |
| US3057782A (en) * | 1958-01-22 | 1962-10-09 | Hoechst Ag | Cross-linked gelatin plasma substitute and production thereof |
| US3035982A (en) * | 1958-12-05 | 1962-05-22 | Merck & Co Inc | Repository vitamin b12 gelatin compositions and preparation thereof |
| DE1276650B (de) * | 1962-05-11 | 1968-09-05 | Iabiotestia Serum Inst G M B H | Verfahren zur Herstellung von als Blutplasmaersatzmittel geeigneten, modifizierten Proteinzubereitungen |
| US3163543A (en) * | 1962-06-19 | 1964-12-29 | J O Whitten Company Inc | Process of producing gelatin products |
| GB1227534A (cg-RX-API-DMAC7.html) * | 1967-08-31 | 1971-04-07 | ||
| US3794729A (en) * | 1971-07-16 | 1974-02-26 | Schering Corp | Inhibiting blood platelet aggregation |
| US4178361A (en) * | 1973-09-10 | 1979-12-11 | Union Corporation | Sustained release pharmaceutical composition |
| US4006220A (en) * | 1975-06-04 | 1977-02-01 | Gottlieb Sheldon K | Compositions and methods useful for repairing depressed cutaneous scars |
| DE2657370C2 (de) * | 1976-12-17 | 1982-11-11 | Hans Dr.med. Dr.med.dent. 8000 München Scheicher | Mittel zum Bedecken und/oder Ausfüllen von Knochendefekten |
| US4164559A (en) * | 1977-09-21 | 1979-08-14 | Cornell Research Foundation, Inc. | Collagen drug delivery device |
| US4224328A (en) * | 1979-04-11 | 1980-09-23 | Sandoz, Inc. | Methods with 1-substituted-4-aryl-quinazolin-2(1H)-ones and thiones and pyrido[2,3-d]pyrimidin-2-ones as platelet aggregation inhibitors |
| JPS5615213A (en) * | 1979-07-13 | 1981-02-14 | Hiroshi Maeda | Ameliorant of peripheral circulatory insufficiency |
-
1980
- 1980-09-25 JP JP55132336A patent/JPS5767521A/ja active Granted
-
1981
- 1981-09-23 US US06/304,943 patent/US4446136A/en not_active Expired - Fee Related
- 1981-09-24 CH CH6172/81A patent/CH649221A5/de not_active IP Right Cessation
- 1981-09-24 IT IT68240/81A patent/IT1195970B/it active
- 1981-09-24 DE DE19813138094 patent/DE3138094A1/de not_active Withdrawn
- 1981-09-25 GB GB8129106A patent/GB2086724B/en not_active Expired
- 1981-09-25 FR FR8118140A patent/FR2490494A1/fr active Granted
- 1981-09-25 CA CA000386695A patent/CA1188222A/en not_active Expired
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR4072M (cg-RX-API-DMAC7.html) * | 1963-06-04 | 1966-04-12 | ||
| FR1529055A (fr) * | 1966-06-18 | 1968-06-14 | Bayer Ag | Procédé pour fabriquer des solutions de gélatine sans agents pyrogènes utilisables comme préparations remplaçant le sang |
| FR2042381A1 (cg-RX-API-DMAC7.html) * | 1969-04-28 | 1971-02-12 | Knox Gelatine Inc | |
| FR2244809A1 (cg-RX-API-DMAC7.html) * | 1973-09-26 | 1975-04-18 | Hausmann Ag Labor | |
| DE2405002A1 (de) * | 1974-02-02 | 1975-08-14 | Trommsdorff Fa H | Loeslichen natives kollagen aus humangewebe und verfahren zu dessen herstellung |
| DE2462222A1 (de) * | 1974-02-02 | 1976-05-06 | Trommsdorff Fa H | Loesliches, natives human-kollagen, dessen nicht-helikale peptide teilweise oder vollstaendig abgetrennt sind |
| US3949073A (en) * | 1974-11-18 | 1976-04-06 | The Board Of Trustees Of Leland Stanford Junior University | Process for augmenting connective mammalian tissue with in situ polymerizable native collagen solution |
| FR2301568A1 (fr) * | 1975-02-18 | 1976-09-17 | Warner Lambert Co | Composition renfermant du collagene soluble et procede de sa preparation |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0330389A3 (en) * | 1988-02-18 | 1990-05-16 | Autogenesis Technologies, Inc. | Human collagen processing and autoimplant use |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS5767521A (en) | 1982-04-24 |
| US4446136A (en) | 1984-05-01 |
| IT8168240A0 (it) | 1981-09-24 |
| GB2086724B (en) | 1985-07-17 |
| DE3138094A1 (de) | 1982-05-06 |
| IT1195970B (it) | 1988-11-03 |
| JPS619287B2 (cg-RX-API-DMAC7.html) | 1986-03-22 |
| GB2086724A (en) | 1982-05-19 |
| CA1188222A (en) | 1985-06-04 |
| CH649221A5 (de) | 1985-05-15 |
| FR2490494B1 (cg-RX-API-DMAC7.html) | 1984-12-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kahn et al. | The assay of hypertensin from the arterial blood of normotensive and hypertensive human beings | |
| Cavarocchi et al. | Superoxide generation during cardiopulmonary bypass: is there a role for vitamin E? | |
| EP0316993B1 (fr) | Compositions pharmaceutiques contenant un dérivé de l'acide 3-hydroxybutanoique choisi parmi les oligomères de cet acide et les esters de cet acide ou de ces oligomères avec du 1,3-butanediol | |
| FR2600255A1 (fr) | Substituant acellulaire des hematies | |
| JP2002505874A (ja) | 細胞活性化測定を使用する診断およびトリアージ方法 | |
| JPH09500366A (ja) | 固形腫瘍及び他の疾患の治療のための薬剤の治療効果を改良する方法 | |
| Coppola et al. | Influence of ozone on haemoglobin oxygen affinity in type-2 diabetic patients with peripheral vascular disease: in vitro studies | |
| Friesenecker et al. | Capillary perfusion during ischemia-reperfusion in subcutaneous connective tissue and skin muscle | |
| FR2460669A1 (fr) | Compositions pharmaceutiques a base de rifamycine sv et ses sels adaptes au traitement du rhumatisme articulaire et procede pour leur preparation | |
| BE1015608A6 (fr) | Traitement des arterites. | |
| Siegfried et al. | Direct cardiovascular actions of two metabolites of linoleic acid | |
| FR2709965A1 (fr) | Compositions pharmaceutiques ayant une activité antithrombotique et procédé pour leur préparation. | |
| FR2490494A1 (fr) | Agent pour ameliorer la circulation sanguine peripherique | |
| Novak et al. | Glutamine and other amino acid losses during continuous venovenous hemodiafiltration | |
| Vachvanichsanong et al. | Non-fatal acute renal failure due to wasp stings in children | |
| EP0532706A1 (en) | REDUCTION OF CARDIOVASCULAR VESSEL OCCLUSIONS USING ASCORBATE AND LIPOPROTEIN BINDING INHIBITORS (a). | |
| WO1980001039A1 (fr) | Materiau fibrinolytique et son procede de fabrication | |
| FR2686251A1 (fr) | Composition pour la cicatrisation d'une plaie. | |
| FR2816213A1 (fr) | Medicament anti-inflammatoire et cicatrisant | |
| US3833724A (en) | Treatment of sickle cell anemia | |
| Hardaway | Trauma, sepsis, and disseminated intravascular coagulation | |
| RU2403909C1 (ru) | Способ лечения сахарного диабета у млекопитающих и интраназальная фармацевтическая композиция для лечения сахарного диабета у млекопитающих | |
| FR2480122A1 (fr) | Procede de preparation d'une glycoproteine a activite immunosupressive, glycoproteine telle qu'ainsi obtenue et medicament la renfermant | |
| JPS5835120A (ja) | 血液循環改善剤 | |
| FR2499409A1 (fr) | Agent therapeutique a base d'une protease acide, pour le traitement des troubles allergiques, des maladies avec immunocomplexe et des tumeurs |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| TP | Transmission of property | ||
| ST | Notification of lapse |